Physician profile
Chester Fox
NPI 1548201551
$6,864.82
in general payments reported to CMS, 2019-2025
38 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,931 · 2020: $1,356 · 2021: $2,319 · 2022: $852 · 2023: $207 · 2024: $61.34 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $407.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $949.26 | 2019-2022 | |
| Insulet Corporation | $881.28 | 2019-2022 | |
| Glaxosmithkline, LLC. | $778.22 | 2019-2022 | |
| Kestra Medical Technology Services, INC. | $775.03 | 2022-2025 | Assure Wcd |
| Novo Nordisk INC | $434.66 | 2019-2022 | |
| Grifols USA, LLC | $345.06 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $326.28 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $318.41 | 2019-2021 | |
| Pfizer INC. | $303.53 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.80 | 2019-2021 | |
| Abbott Laboratories | $167.67 | 2019-2021 | |
| Dexcom, INC. | $157.96 | 2021-2024 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $137.17 | 2019-2021 | |
| Lilly USA, LLC | $131.97 | 2019-2021 | |
| Amgen INC. | $120.67 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $92.19 | 2025 | Nuplazid |
| Mannkind Corporation | $64.04 | 2019-2021 | |
| Mylan Specialty L.P. | $63.48 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $61.52 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $59.36 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $53.57 | 2021 | |
| Eisai INC. | $52.19 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.66 | 2021-2022 | |
| Allergan, INC. | $34.67 | 2020 | |
| Philips North America LLC | $29.09 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $29.05 | 2021-2022 | |
| Oxford Immunotec USA INC | $27.70 | 2020 | |
| Ironwood Pharmaceuticals, INC | $26.83 | 2020 | |
| Merck Sharp & Dohme LLC | $22.35 | 2022 | |
| Sunovion Pharmaceuticals INC. | $22.13 | 2019 | |
| Neuronetics, INC. | $21.76 | 2019 | |
| Valeritas, INC. | $17.69 | 2019 | |
| Daiichi Sankyo INC. | $17.62 | 2020 | |
| Amarin Pharma, INC. | $16.50 | 2019 | |
| Almatica Pharma LLC | $15.78 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.67 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chester Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.